Cerevel Therapeutics to Report Fourth Quarter 2021 Financial Results and Pipeline Update on Tuesday, March 1, 2022
February 16, 2022 06:30 ET
|
Cerevel Therapeutics
CAMBRIDGE, Mass., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced...
Cerevel Therapeutics Announces Positive Topline Results for Darigabat in Phase 1 Clinical Trial in Acute Anxiety
February 15, 2022 06:30 ET
|
Cerevel Therapeutics
In healthy volunteers, both the 7.5 mg and 25 mg twice-daily doses of darigabat demonstrated a clinically meaningful and statistically significant improvement in the Panic Symptoms List score after...
Cerevel Therapeutics to Present at 40th Annual JP Morgan Healthcare Conference: Additional Details of Phase 2 Program for Emraclidine (CVL-231) in Schizophrenia to be Presented
January 10, 2022 06:30 ET
|
Cerevel Therapeutics
Emraclidine now the international nonproprietary name (INN) for CVL-231, an M4-selective positive allosteric modulator in development for schizophrenia Company expects to initiate Phase 2 program for...
Cerevel to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 03, 2022 07:00 ET
|
Cerevel Therapeutics
CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a global company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today...
Cerevel Therapeutics and Herophilus Announce Collaboration to Evaluate Novel Neuroimmune Modulating Therapeutic Strategies for Schizophrenia
December 16, 2021 07:00 ET
|
Cerevel Therapeutics
CAMBRIDGE, Mass. and SAN FRANCISCO, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience...
Cerevel Therapeutics Reports Third Quarter 2021 Financial Results and Pipeline Updates
November 10, 2021 06:30 ET
|
Cerevel Therapeutics
Phase 1 data for darigabat in acute anxiety now expected by the end of Q1 2022 Submissions of additional PK/PD data for CVL-231 in schizophrenia accepted for presentation at the Annual Meeting of the...
Cerevel Therapeutics to Participate at Upcoming Virtual Investor Conferences
November 01, 2021 06:30 ET
|
Cerevel Therapeutics
CAMBRIDGE, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that...
Cerevel Therapeutics to Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021
October 20, 2021 06:30 ET
|
Cerevel Therapeutics
CAMBRIDGE, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced...
Cerevel Therapeutics Hosts Virtual R&D Event to Review CVL-871 in Dementia-Related Apathy and Provide Update on CVL-231 for the Treatment of Schizophrenia
October 07, 2021 07:00 ET
|
Cerevel Therapeutics
Live webcast today from 10:00 to 11:30 a.m. ET CAMBRIDGE, Mass., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain...
Cerevel Therapeutics Announces Departure of CFO Kathy Yi
September 21, 2021 17:00 ET
|
Cerevel Therapeutics
Current Chief Accounting Officer Mark Bodenrader named as interim CFO Search underway for permanent successor CAMBRIDGE, Mass., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq:...